Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Hematologic and Oncologic Associated Rheumatic Syndromes

Poster Session B

Session: (1088–1122) Immunological Complications of Medical Therapy Poster

1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy

Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1
Figure 1: Frequency of Pre-Immune Checkpoint Inhibitor Rheumatic Diseases in the RADIOS Study

Figure 2: Ever use of disease modifying anti-rheumatic drugs (DMARDs) prior to immune checkpoint inhibitor (ICI) start

Table 1: Demographics and baseline characteristics for patients with pre-ICI Rheumatic Disease

    Abstract Poster Presenter(s)

  • Laura Cappelli, MD

    Johns Hopkins School of Medicine
    Baltimore, MD, United States

    Disclosure information not submitted.


Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies commonly used to treat malignancies but can cause flares or unrelated immune-related adverse events (irAEs) in patients with pre-existing rheumatic disease prior to ICI initiation (pre-ICI RD). As patients with pre-ICI RD were excluded from initial ICI studies, there is still a paucity of information about risks of ICI treatment and how to manage pre-ICI RD while patients are on ICIs.

Methods: Rheumatic Adverse Events Due to Cancer Immunotherapy Observational Studies (RADIOS) is a United States-based academic consortium of 12 sites prospectively collecting data to evaluate outcomes of patients with pre-ICI RD who receive cancer immunotherapy. Patients were included if they had pre-ICI RD and had a baseline visit with rheumatology. Descriptive statistics were calculated for the cohort’s demographics (including age, sex, race, ethnicity), cancer characteristics, ICI use at enrollment, and prior treatment for autoimmune disease; clinical disease activity index (CDAI) was calculated for those with inflammatory arthritis. Data on irAE development and autoimmune disease treatment were queried for follow up visits.

Results: As of 4/1/2025, 78 patients with pre-ICI RD were enrolled into the cohort; mean age was 67 years and 54% were female. Inflammatory arthritis was the most common diagnosis (39%) followed by systemic lupus (5.9%) and Sjogren’s disease (5.9%) (Figure 1). Melanoma was the most common cancer type followed by non-small cell lung cancer. The majority of patients had stage 4 cancer, and anti-PD-1 was the most common category of ICI used (Table 1). Patients had been previously treated for their RD with a wide variety of DMARDs, most commonly TNF-inhibitors, methotrexate, and hydroxychloroquine (Figure 2). At RADIOS enrollment, 23 (29.5%) were currently on corticosteroids. For those with inflammatory arthritis and CDAI available (n=36), mean CDAI was 11.4 (SD 11.4) and most had low disease activity or remission (n=20, 55.6%). The most common non-rheumatic irAEs developed were rash and pneumonitis (n=5 for both). At follow up visits, TNF-inhibitors were the most administered biologics (n=9) followed by IL-6R inhibitors (n=7); methotrexate (n=15) and hydroxychloroquine (n=13) were the most common conventional synthetic DMARDs administered. No patients received JAK-inhibitors in follow-up.

Conclusion: By characterizing treatment patterns and outcomes in diverse rheumatic diseases, this multi-institutional, prospective research collaboration will improve knowledge regarding ICI safety for patients with rheumatic diseases who require ICI therapy for cancer.